Local American Working Group‘s head Rūta Pumputienė commented on Lithuania‘s new medicines’ reimbursement system and potential for improvement to increase Lithuanian patients‘ access to innovative oncological medicines.
Lithuanian Ministry of Health deserves compliments for getting involved in the dialogue around the new reimbursement system itself, as well as involving all stakeholders. They have also taken into account the comments of doctors, patients, and industry’s representatives. Finally, they have eliminated a much-debated EUR 30,000 medicine value benchmark from the draft law.
With the new criteria come positive changes. Firstly, it will hopefully help diminish discrimination towards oncological medicines. Secondly, a step towards a flexible financial benchmark to reimburse medicines has been taken. Nevertheless, there is still plenty of room to improve – especially in terms of including innovative oncological medicines into the reimbursable medicines lists.
To read the full article click HERE
Local American Working Group (LAWG) is a standing committee established under the American Chamber of Commerce in Lithuania, which represents innovative pharmaceutical, biotechnological and life sciences industry based in Lithuania.
Learn more about the committee click HERE